HLUYY News and Press, H Lundbeck A/S S/Adr From 04/07/20

Drug development is an inherently risky and challenging endeavor, but not all drug development is the same. Some areas, including drugs for the central nervous system (or CNS), have notoriously below-average success rates, and H. Lundbeck ’s ( OTCPK:HLUYY ) ( LUN.CO ) recent clinical f...

Appearing motivated to release all the bad news at once, H. Lundbeck A/S ( OTCPK:HLUYY -4.0% ) announces another failed clinical trial, this time a Phase 2a study evaluating Lu AG06466 in adults with a movement disorder called Tourette syndrome . More news on: H. Lundbeck A/S, H. Lu...

H. Lundbeck A/S ( OTCPK:HLUYY -4.0% ) slips on light volume on the heels of its announcement of unsuccessful results from a Phase 2a clinical trial, AMBLED , evaluating foliglurax in Parkinson's disease (PD) patients experiencing motor complications from levodopa therapy. More news on...

Investors often gravitate toward pharmaceutical stocks due to the perception that the sector offers less volatility than other sectors, but that has not been the case for H. Lundbeck ( HLUYY ) (LUN.KO), and the shares have remained quite volatile as investors try to figure out the confoundin...

The following slide deck was published by H. Lundbeck A/S in conjunction with their 2019 Q4 earnings Read more ...

The following slide deck was published by H. Lundbeck A/S in conjunction with this Read more ...

Holding H. Lundbeck A/S ( OTCPK:HLUYY ) ( LUN.CO ) (“Lundbeck”) has definitely had its ups and downs; while I lightened up some during the very optimistic summer of 2018, the company has nevertheless had its challenges with multiple late-stage pipeline failures, a relatively ba...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) rose last week from 3,267.22 points on Monday’s (September 16) open to 3,319.26 points as of 12:37 p.m. EDT on Friday (September 20). On Monday, Alder BioPharmaceuticals (NASDAQ: ALDR ) announced that it is going to be acquired by D...

Danish drugmaker H. Lundbeck A/S ( OTCPK:HLUYY ) ( LUN.KO ) (“Lundbeck”) made it clear that they were going to rebuild their revenue and clinical pipeline through M&A, with management highlighting around $4 billion to $5 billion in available capital and a preference for l...

Alder BioPharmaceuticals (NASDAQ: ALDR ) announced on Monday (September 16) that it has struck a deal to be acquired by Lundbeck A/S (OTC Pink: HLUYY ) in a US$2 billion takeover. The Denmark-based company’s move to acquire Alder BioPharma puts Lundbeck in a position to potentially ...